Ultomiris (ravulizumab-cwvz) — Medica
Atypical hemolytic uremic syndrome (aHUS)
Initial criteria
- Patient does not have Shiga toxin Escherichia coli-related hemolytic uremic syndrome
- Medication is prescribed by or in consultation with a nephrologist
Approval duration
1 year